An international clinical trial led by researchers including Professor Chloe Orkin of Queen Mary University of London has ...

"As the only two-drug, non-integrase strand transfer inhibitor, tenofovir-free regimen, Idvynso expands therapeutic diversity beyond the currently available oral treatment options," Eliav Barr, senior ...

Genetic sequencing of peptides in rebound virus in individuals with HIV who had analytic treatment interruptions (ATIs) confirmed the peptides’ expression in HIV-1 infection, according to data ...

Merck is carving out its own place in the evolving HIV treatment space with an FDA approval for its Idvynso, a combination regimen that brings its novel islatravir to market for the first time and ...

Are we unraveling years of progress on fighting HIV/AIDS? For the past two decades, the US has led the global response to a virus and disease that have together claimed more than 40 million lives. But ...

An experimental drug originally developed to treat cancer may help clear HIV from infected cells in the brain, according to a new study. By targeting infected cells in the brain, drug may clear virus ...

A new single-pill HIV treatment has proved as effective as regimens of up to 11 tablets a day in suppressing the virus in hard-to-treat patients. It’s “a potential breakthrough for a growing cohort of ...

Dec 15 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Monday its experimental HIV treatment was found to be statistically non-inferior to its top-selling drug Biktarvy in a late-stage ...

As the annual U.S. Conference on HIV/AIDS (USCHA) kicks off in Washington, D.C., this week with a focus on aging with HIV, Gilead Sciences is rolling out a corresponding awareness campaign ...

A 21-year-old man became the latest person potentially cured of HIV after receiving stem cells from a donor with a rare ...